Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 17/20 | 0.70 |
| ▸ | ITGAV | P06756 | 17/20 | 0.70 |
| ▸ | ITGB1 | P05556 | 8/20 | 0.70 |
| ▸ | CYSLTR2 | Q9NS75 | 1/20 | 0.53 |
| ▸ | CYSLTR1 | Q9Y271 | 1/20 | 0.53 |
| ▸ | ITGB5 | P18084 | 4/20 | 0.52 |
| ▸ | ITGB6 | P18564 | 3/20 | 0.52 |
| ▸ | ITGA2B | P08514 | 4/20 | 0.52 |
| ▸ | ITGA5 | P08648 | 3/20 | 0.44 |
| ▸ | MDM4 | O15151 | 1/20 | 0.44 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6326832 | 0.93 | ITGB3 (0.74) | ITGB3ITGAVITGB1CYSLTR2CYSLTR1 | |
| SCHEMBL6319031 | 0.82 | ITGB3 (1.00) | ITGB3ITGAVITGB1ITGB5ITGB6 | |
| SCHEMBL6318113 | 0.80 | ITGB3 (0.80) | ITGB3ITGAVITGB1ITGB5ITGB6 | |
| SCHEMBL6831339 | 0.78 | ITGB3 (0.72) | ITGB3ITGAVITGB1ITGB5ITGB6 | |
| SCHEMBL6319149 | 0.77 | ITGB3 (0.66) | ITGB3ITGAVITGB1ITGB5ITGB6 | |
| SCHEMBL6833670 | 0.77 | ITGB3 (0.67) | ITGB3ITGAVITGB1ITGB5ITGB6 | |
| SCHEMBL7031930 | 0.74 | ITGB3 (0.63) | ITGB3ITGAVITGB1ITGB5ITGB6 | |
| SCHEMBL6318388 | 0.74 | ITGB3 (0.62) | ITGB3ITGAVITGB1ITGB5ITGB6 | |
| SCHEMBL6771845 | 0.73 | ITGB3 (0.71) | ITGB3ITGAVITGB1ITGB5ITGB6 | |
| SCHEMBL12209855 | 0.72 | AKR1C3 (0.56) | CYSLTR2CYSLTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6900232-B2 | Cycloalkyl alkanoic acids as integrin receptor antagonists | PHARMACIA CORPORATION (US) | 2005-05-31 | — | — | US | claimed |
| US-20040043988-A1 | Cycloalkyl alkanoic acids as intergrin receptor antagonists | PHARMACIA CORPORATION | 2004-03-04 | — | — | US | claimed |
| US-20020077321-A1 | Cycloalkyl alkanoic acids as integrin receptor antagonists | PHARMACIA CORPORATION | 2002-06-20 | — | — | US | claimed |
| US-6949578-B2 | Cycloalkyl alkanoic acids as integrin receptor antagonists | PHARMACIA CORPORATION (US) | 2005-09-27 | — | — | US | disclosed |
| US-6921767-B2 | Cycloalkyl alkanoic acids as integrin receptor antagonists derivatives | PHARMACIA CORPORATION (US) | 2005-07-26 | — | — | US | disclosed |
| US-6900232-B2 | Cycloalkyl alkanoic acids as integrin receptor antagonists | PHARMACIA CORPORATION (US) | 2005-05-31 | — | — | US | disclosed |
| US-20040259869-A1 | Cycloalkyl alkanoic acids as integrin receptor antagonists | PHARMACIA CORPORATION | 2004-12-23 | — | — | US | disclosed |
| US-20040092538-A1 | Cycloalkyl alkanoic acids as integrin receptor antagonists derivatives | PHARMACIA CORPORATION | 2004-05-13 | — | — | US | disclosed |
| US-20040043988-A1 | Cycloalkyl alkanoic acids as intergrin receptor antagonists | PHARMACIA CORPORATION | 2004-03-04 | — | — | US | disclosed |
| EP-1289960-A2 | CYCLOALKYL ALKANOIC ACIDS AS INTEGRIN RECEPTOR ANTAGONISTS | Pharmacia Corporation (US) | 2003-03-12 | — | — | EP | disclosed |
| US-20020077321-A1 | Cycloalkyl alkanoic acids as integrin receptor antagonists | PHARMACIA CORPORATION | 2002-06-20 | — | — | US | disclosed |
| WO-2001096307-A2 | CYCLOALKYL ALKANOIC ACIDS AS INTEGRIN RECEPTOR ANTAGONISTS | PHARMACIA CORPORATION (US) | 2001-12-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040043988-A1 | Cycloalkyl alkanoic acids as intergrin receptor antagonists | ADGRE5, ITGA5, ADGRF1 | ITGB3 5/4885ITGAV 7/4885ITGB1 8/4885 |
| US-20040092538-A1 | Cycloalkyl alkanoic acids as integrin receptor antagonists derivatives | ITGA5, ITGB5, ITGB3 | ITGB3 3/4885ITGAV 6/4885ITGB1 5/4885 |
| US-20040259869-A1 | Cycloalkyl alkanoic acids as integrin receptor antagonists | ITGA5, ITGB5, ITGB3 | ITGB3 3/4885ITGAV 7/4885ITGB1 6/4885 |
| US-20020077321-A1 | Cycloalkyl alkanoic acids as integrin receptor antagonists | ITGA5, ITGB5, ITGB3 | ITGB3 3/4885ITGAV 7/4885ITGB1 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.